Physician profile
Billy X Pan
NPI 1760828248
$249,515.66
in general payments reported to CMS, 2019-2025
34 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $17K · 2022: $32K · 2023: $53K · 2024: $75K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Food and Beverage: $18K · Travel and Lodging: $14K · Honoraria: $2,132 · Entertainment: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,262.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,882.79 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $34,625.00 |
| Food and Beverage | $17,759.66 |
| Travel and Lodging | $14,473.62 |
| Honoraria | $2,132.44 |
| Entertainment | $499.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $52,846.77 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Abbvie INC. | $45,370.88 | 2022-2025 | |
| Glaukos Corporation | $44,225.36 | 2019-2025 | Idose, Idose Trio, Travoprost Intraocular Implant - Idose |
| Aerie Pharmaceuticals, INC. | $28,310.36 | 2019-2021 | |
| Nova Eye, INC. | $24,685.56 | 2022-2025 | |
| Alcon Vision LLC | $18,694.06 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Allergan, INC. | $9,555.75 | 2019-2022 | |
| Sight Sciences, INC. | $8,826.99 | 2021-2024 | Omni Surgical System, Tearcare System |
| New World Medical,INC. | $5,689.89 | 2022-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Alcon Research LLC | $4,178.60 | 2023-2024 | |
| Ivantis, INC | $2,658.03 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $569.74 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $532.09 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $482.81 | 2022-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $407.39 | 2019-2025 | Cequa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $375.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $336.27 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $261.22 | 2023-2024 | Iolmaster 700, Quatera 700 |
| Oyster Point Pharma, INC. | $255.95 | 2022-2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec, INC. | $210.08 | 2025 | |
| Lumibird Medical INC. | $192.28 | 2020 | |
| Rxsight INC | $147.74 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Ocular Therapeutix, INC. | $126.72 | 2020-2025 | Dextenza |
| Akorn Operating Company LLC | $117.52 | 2021 | |
| Kala Pharmaceuticals, INC. | $78.72 | 2021-2022 | |
| Amgen INC. | $64.60 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $63.74 | 2022-2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $61.82 | 2022 | |
| Omeros Corporation | $46.58 | 2021 | |
| Biotissue Holdings INC. | $41.71 | 2023-2025 | |
| Horizon Therapeutics Plc | $36.31 | 2022 | |
| Dompe US, INC. | $23.86 | 2024 | Oxervate |
| Akorn, INC. | $21.27 | 2020 | |
| Harrow Eye, LLC | $19.23 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.